S017 The Quality Improvement and Innovation Symposium
DESCRIPTION
The first part of the symposium will feature a panel discussion and brief talks on ways to improve access in dermatology. Examples of innovative access projects will be featured that highlight the use of technology and algorithms for prioritization of urgent appointment. The second half of the symposium will feature the AAD's Resident Quality Improvement Award and Innovations in Quality Improvement Award Recipients.
LEARNING OBJECTIVES
Demonstrate effective patient access models for scheduling of clinical practice patients
Design interventions to improve patient access in dermatology through innovative scheduling algorithms, implementation of technology, and prioritization of urgency of visits
Discuss ways in which quality improvement can be integrated into clinical care across various settings, such as private practice, industry, and academic practice.
SCHEDULE
1:00 PM
Introduction to Access Issues in Dermatology
Martina J Porter, MD, FAAD, Ramona Behshad, MD, FAAD
1:20 PM
Panel Discussion: Improving Access in Dermatology
Rita Khodosh, MD, PhD, FAAD
2:20 PM
Creating an Equitable Dermatology Safety Net for Temporarily Disabled Patients: Improving Access, Reducing Readmissions, and Enhancing Patient-Centered Care
Gideon Smith, MD, FAAD
2:45 PM
Identifying and Reducing Low-Risk Total Body Skin Exams
Nikki Trupiano, MD, Anjani Sheth, MD, MPH
2:55 PM
Streamline the Screen Time: Improving EMR Efficiency through EPIC Express Lanes
Albert Zhou, MD, PhD
3:05 PM
Optimizing Patient Communication Intake and Triage by EHR-embedded tools to Improve Patient Outcomes and Reduce Physician Burden
Kelly Flanagan, MS
3:15 PM
Implementation of Epic-Compatible Artificial Intelligence Scribing to Reduce Dermatology Resident Burnout
Kayla Brockmeyer, MD, Lauren Banner, MD
3:25 PM
Improving Prevention of Atherosclerotic Cardiovascular Disease in Patients with Psoriasis
David Weiner, MD, MBE
3:35 PM
Improving Dermatologic Health and Hygiene for People Experiencing Homelessness: A Bronx Shelter Quality Improvement Project
DIRECTOR
Martina J Porter, MD, FAAD
SPEAKERS
Lauren Banner, MD
Ramona Behshad, MD, FAAD
Kayla Brockmeyer, MD
Kelly Flanagan, MS
Rita Khodosh, MD, PhD, FAAD
Anjani Sheth, MD, MPH
Gideon Smith, MD, FAAD
Nikki Trupiano, MD
David Weiner, MD, MBE
Albert Zhou, MD, PhD
DISCLOSURES
Lauren Banner, MD
No financial relationships exist with ineligible companies.
Ramona Behshad, MD, FAAD
Castle Biosciences, Inc – Investigator(Grants/Research Funding);
Kayla Brockmeyer, MD
No financial relationships exist with ineligible companies.
Kelly Flanagan, MS
No financial relationships exist with ineligible companies.
Rita Khodosh, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Martina J Porter, MD, FAAD
AbbVie – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Alumis – Consultant(Fees); AnaptysBio – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Bayer – Investigator(Grants/Research Funding); Beth Israel Deaconess Medical Center – Other(Patent royalties or other compensation for Intellectual Property Rights); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(No Compensation Received); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Consultant(Fees); Merck – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Mirador – Investigator(Grants/Research Funding); Moonlake – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Investigator(Grants/Research Funding); Oasis Pharmaceuticals – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Prometheus Laboratories, Inc. – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Trifecta Clinical – Consultant(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Zura Bio – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Anjani Sheth, MD, MPH
No financial relationships exist with ineligible companies.
Gideon Smith, MD, FAAD
No financial relationships exist with ineligible companies.
Nikki Trupiano, MD
No financial relationships exist with ineligible companies.
David Weiner, MD, MBE
No financial relationships exist with ineligible companies.
Albert Zhou, MD, PhD
No financial relationships exist with ineligible companies.